leadf
logo-loader
viewAmplia Therapeutics Ltd

Amplia Therapeutics CEO says dosing in its phase one trial is 'enormous' milestone

Amplia Therapeutics Limited's (ASX:ATX) Dr John Lambert speaks to Proactive's Andrew Scott following the news they've begun dosing the first volunteers in its Phase 1 clinical trial of AMP945. The molecule's being developed for difficult-to-treat cancers and fibrotic diseases. Amplia expects to complete dosing in the trial during the first half of next year, which should allow reporting of top-line results around the middle of 2021.

Quick facts: Amplia Therapeutics Ltd

Price: 0.295 AUD

ASX:ATX
Market: ASX
Market Cap: $31.78 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Amplia Therapeutics Ltd named herein, including the promotion by the Company of Amplia Therapeutics Ltd in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Alicanto Minerals intersects strong visuals at The Swamp Thing target at...

Alicanto Minerals Ltd's (ASX:AQI) Peter George tells Proactive's Andrew Scott they've intersected strong visuals from initial drilling at The Swamp Thing target within its Greater Falun copper-gold project in Sweden. It's intersected a thin 30-centimetre semi-massive sulphide skarn...

14 hours, 18 minutes ago

2 min read